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Background: The infused cell dose is an important deter-
minant of engraftment after CB transplantation. Thus, cell
loses during manufacturing and samples for testing must be
minimized. The AutoXpress (AXP) system is used for pro-
cessing of HPC-CB FDA licensed products in our Bank. With
this, collected CB is separated into three components (frac-
tions): red blood cells (RBC), plasma (P) and mononuclear
cells (MNC), which represent the ﬁnal HPC-CB product.
Methods: To optimize the number of HPC-CB cells to be
cryopreserved, we explored the suitability of RBC or P
samples as surrogates of the ﬁnal product for testing of
bacteria/fungi contamination. We evaluated the distribution
of 7 microorganisms, spiked into whole CB collections at
known concentrations (triplicate studies for each microor-
ganism), into each of the three post-processing fractions.
Further, a Rapid Microbiological Method (VersaTREK, Ther-
moFisher Scientiﬁc, OH) was used for the detection of
bacteria/fungi in samples of RBC, MNC and P and compared
to the gold standard bacteriology method (USP<71>).
Results: Spiked microorganisms were distributed differ-
ently: Pseudomonas aeruginosa, Enterococcus faecalis, Staph-
ylococcus epidermidis, Propionibacterium acnes (Pac) and
Bacillus subtiliswere concentrated preferentially in the MNC,
while Candida albicans and Aspergillus Niger were more so in
the RBC fraction. Nonetheless, the VersaTREK detected all
microorganisms (sensitivity 100 CFU/ bottle) from all three
fractions with a comparable time to detection (TTD) for RBC
and MNC samples (all  14 days). A 10-fold higher P volume
(5 mL) was used to detect growth at a TTD comparable to
MNC or RBC samples. Further, delayed detection, due to
partial inhibition of the growth of Pac, was seen with the
higher P volume.
Summary: The VersaTREK/Redox detects microorganisms
with sensitivity comparable to the standard method in all
three fractions after AXP-processing. Use of MNC or RBC did
not impact signiﬁcantly the ability or time to detection. The
use of samples from the RBC or P fractions, or possibly,
a combination of both for sterility screening of HPC-CB
products will preserve approx. 5% of the ﬁnal product
volume for transplant use.
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Background: After hematopoietic cell transplantation (HCT),
the risk of acute graft-vs.-host disease (GVHD) is increased in
male recipients of female grafts. Disparities for the male-
associated H-Y and other minor histocompatibility antigens
(mHAs) have the capacity to sensitize alloreactive donor T
cells and cause GVHD in HLA-matched recipients. We asked
whether regulatory T cells (Treg) exist speciﬁc for human
mHA.
Methods and Results: Tregs from normal donors were iso-
lated by CD25 immunoabsorption and cultured with
dendritic cells (DC) from HLA-matched siblings in the pres-
ence of IL-2, IL-15 and rapamycin. We detected a 15-fold
increase in 3H-TdR uptake at 6 days in Treg cultures stimu-
lated by HLA-identical, mHA incompatible sibling DC
compared to self-DC. The median precursor frequency of
mHA-speciﬁc Treg is 1.3 (range, 0.1-13.5) cells per million
total blood CD4 T cells, while the median frequency of mHA-
speciﬁc conventional CD4 (Tconv) is 25 (range, 3-141) per
million total blood CD4 T cells. Among 13 HLA-identical
sibling pair tested in any gender combination, there was a 26
(range, 8 to 39)-fold excess mHA-speciﬁc Tconv over mHA-
speciﬁc Treg in the donor blood. It is the predominance of
alloreactive Tconv over Tregs that drives the immune
response causing GVHD. Puriﬁed Tregs were expanded in
culturewith for 12 days with DC from aHLA-identical sibling,
IL-2, IL-15 and rapamycin (n¼5), and the frequency of mHA-
speciﬁc Tregs expanded 147 to 394-folds. Tregs responded to
re-stimulation with DC from the original HLA-identical
sibling, but not self-DC. The mHA-speciﬁc Tregs exhibited
antigen speciﬁc suppression. When Tregs were cultured at
limiting dilution, we obtained 4 mHA-speciﬁc Treg clones
that retained TGFb secretion in response to the sibling's
mHA-disparate DC but not self-DC. One of these clones from
a female donor responded to HY-antigen DBY expressed on
self-APC after gene transduction and not UTY or DC alone,
while another clone responded to UTY not DBY or self-DC
alone. We adapted our protocol to GMP-compatible, large
scale expansion of Treg from apheresis of 3.7 x 1010cells.
Cultured Tregs maintained high levels of Foxp3 expression
and demethylation of the Treg-speciﬁc Foxp3 gene promoter
of the end-culture. mHA-speciﬁc Tregs were enriched 324-
folds during the 12-day culture, indicating that we will be
able to produce enough cells to exceed the numbers of mHA-
speciﬁc CD4 Tconv (CD4 Tconv/Treg ratio, range 8-29) using
a leukapheresis. We could not detect alloreactive T cells in
this culture, besides TGFb-producing Tregs. The end-of-
culture Tregs produced allospeciﬁc suppression with an IC50
between 1:1,000 and 1:10,000.
Conclusions: We demonstrated for the ﬁrst time that it is
possible to detect and expand mHA speciﬁc Tregs from HLA-
matched sibling pairs. Immunotherapy with mHA-speciﬁc
Tregs against ubiquitous mHAs may prevent GVHD.163
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210 S195Chimeric antigen receptors (CARs) are artiﬁcial mole-
cules that can be used to redirect T cell immune response
against antigens expressed on the surface of tumor cells.
Although promising, most current protocols expand engi-
neered T cells non-speciﬁcally using IL-2 and OKT3, which
decreases the frequency of transgenic populations over
time. Additionally, cell expansion using conventional cul-
tureware is complicated and labor intensive, which limits
the broader application of this therapy. With the grant
support from Production Assistance for Cell Therapy
(PACT), we assessed whether CAR T cell manufacture could
be optimized and streamlined by: (i) supplementing non-
speciﬁc stimuli (IL-2) with an artiﬁcial antigen presenting
cell (a-APC) engineered to express cognate antigen and co-
stimulatory molecules, and (ii) efﬁciently and rapidly
expanding cells in a simple and scalable gas permeable
culture device (G-Rex). As a proof of principle, we sought to
expand T cells engineered with a CAR targeting the prostate
cancer antigen, PSCA. We ﬁrst generated an a-APC cell line
by modifying K562 cells, which expressed a range of co-
stimulatory molecules including CD80, CD86, and 41BBL,
with a retroviral vector encoding the PSCA antigen. After
the co-culture of CAR-PSCA T cells with the irradiated
a-APC, we found that a-APCs co-expressing PSCA antigen,
CD80, and 41BBL were the most effective in inducing T cell
expansion, with a 1.9 fold increase in total cell numbers
when compared with CAR T cells expanded in the presence
of IL2 alone. We also saw an increase in the frequency of
transgenic CAR T cells which increased from 36.5% to 88.1%
after 10 days of culture. In contrast, the percentage of
transgenic T cells was sustained when cultured in the
presence of IL2 (36.5% on day 0 and 37.2% on day 10). Thus,
culture of CAR-T cells with antigen-expressing a-APCs not
only improves total cell output, but also enriches for
transgene-expressing. Next, to assess whether we could
scale up cell production we transferred the engineered
a-APCs and CAR-PSCA T cells (at a 2:1 ratio) into a static
GMP-compliant G-Rex with a surface area of 100cm2. In
these G-Rex devices, O2 and CO2 are exchanged across
a silicone membrane at the base, which allows for the
addition of an increased depth of medium above the cells.
These culture conditions have been shown to increase cell
output without increasing the number of cell doublings.
From an initial seeding density of 25E+06 CAR T cells, we
obtained a total of 2200-2500E+06 cells within 10 days of
culture. Thus, without any intervention we obtained a 93
fold increase in cell numbers using only 1 liter of T cell
culture media. We also observed an enrichment of trans-
genic T cells (from 33.2% to 81.7%, a 2.41.2 fold increase,
after 10 days of culture). Taken together the total T cell fold
expansion (93) and the enrichment for the transgene
(2.41.2), we calculate a 223.5111.6 fold expansion of CAR
T cells.164
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Background: Cytomegalovirus (CMV) continues to be an
important human pathogen in allogeneic hematopoietic
cell transplant (allo-HCT) recipients. Both CD4+ and CD8+
T cells are important for long-term control of the virus.
Identiﬁcation of CMV-speciﬁc T cell epitopes has primarily
focused on CD8+ T cell epitopes. Adoptive transfer of
CMV-speciﬁc CD4+ T cells has previously been associated
with prolonged protection from reactivation and CMV
disease.
Aims: To characterize the repertoire and restriction of CMV-
speciﬁc CD4+ T cell responses against immediate early
antigen 1 and 2 (IE1 and IE2) in 16 healthy, HLA-typed, CMV+
donors.
Methods: We performed IFN-g ELISPOT assays ex vivo on
PBMCs from CMV+ donors using 187 peptides (15 amino
acids long and overlapping 10 amino acids) spanning the
entire IE1 and IE2. These peptides were distributed into
individual microtiter wells, PBMCs from each donor were
added and incubated, and the resulting responses were
measured by IFN-g ELISPOT analysis. To validate the
peptide-speciﬁcity and to establish the phenotype of the
responding cells, peptides eliciting IFN-g release in the
ELISPOT analysis were subsequently used to stimulate
PBMCs in vitro for 12-14 days followed by ﬂow cytometric
intracellular cytokine secretion assay. For the identiﬁed
CD4+ T cell responses, peptide-MHC class II (MHCII) afﬁnity
measurements were used to suggest the most likely
restricting element(s) among the donors MHCII molecules.
To validate MHCII restriction element(s), MHCII tetramers
(TMR) were generated and used to label in vitro stimulated
PBMCs.
Results: We have identiﬁed 27 CD4+ T cell epitopes in IE1
and IE2; 19 of these are novel. Several CD4+ T cell epitopes
appeared to be immunodominant. Thus, one DRB1*0101-
restricted IE2 epitope was recognized by 5/5 DRB1*0101-
positive donors, two DRB1*0301-restricted epitopes, one in
IE2 and one in IE1, were recognized by 4/4 and 4/4
DRB1*0301-positive donors, respectively, and one
DRB5*0101-restricted IE1 epitope was recognized by 4/4
DRB5*0101-positive donors. Additional epitopes appear to be
immunodominant by functional analysis, but have not yet
been validated with MHCII TMRs.
Conclusions: We have found multiple novel CD4+ epitopes
in CMV IE1 and IE2 of which several have been validatedwith
MHCII TMRs. These epitopes could be used to explore the
reconstitution of CMV-speciﬁc CD4+ T cells following allo-
HCT, and they could represent promising candidates for
adoptive CD4+ T cell transfer.166
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